The benefit and risk of addition of PD-1/PD-L1 inhibitors to chemotherapy for advanced cervical cancer: a phase 3 randomized controlled trials based meta-analysis
Abstract Background Chemotherapy has been confirmed as an effective treatment for advanced cervical cancer. However, whether combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) offers superior efficacy remains a subject of debate. This meta-analysis aims to compare the antitumor effects and safe...
Saved in:
| Main Authors: | Deping Luo, Ying Yu, Qi Wang, Tao Peng, Chan Li, Wenxiong Zhang, Jing Huang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-13843-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-analysis
by: Chao Song, et al.
Published: (2025-05-01) -
PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone as the first line treatment for advanced biliary tract cancer: a pooled analysis of KEYNOTE-966 and TOPAZ-1 trails
by: Jiashou Wang, et al.
Published: (2025-06-01) -
Neoadjuvant chemotherapy with or without PD-1/PD-L1 inhibitors in resectable esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials
by: Ye Zhang, et al.
Published: (2025-05-01) -
PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Chinese patients with advanced non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials
by: Jianfei Zhang, et al.
Published: (2025-07-01) -
Response efficacy of PD-1 and PD-L1 inhibitors in salivary gland cancers: a systematic review and meta-analysis
by: Zahra Babamohamadi, et al.
Published: (2025-04-01)